Navigation Links
AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Date:5/14/2008

y study, being led by Prof. Frans M.J. Debruyne, M.D., Ph.D., from The Netherlands, will enroll approximately 400 patients in Europe.

The third Phase 3 trial, for which first patient dosing was announced today, is an open-label, single-armed multi-center safety study involving approximately 500 patients in both North America and Europe, and is being led by Joel Kaufman, M.D., Associate Clinical Professor of Urology, University of Colorado School of Medicine, Denver, Colorado, and Urology Research Options, Aurora, Colorado.

The primary endpoint for both North American and European efficacy studies is the change in I-PSS between baseline and Week 52. Other efficacy endpoints include additional measures of BPH-symptom progression and the need for BPH-related surgery. Safety endpoints include changes in sexual function. Other important endpoints include plasma changes in levels of testosterone, and assessment of other adverse events.

The cetrorelix Phase 3 program is based on comprehensive clinical practice guidelines to ensure quality control, including input from expert advisors on study design, publishing results in peer-reviewed journals and discussion of the studies with regulatory agencies.

Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men - affecting more than 20 million men in the United States - but its etiology is far from being completely understood. Data from ongoing research suggest BPH and its associated lower urinary tract symptoms (LUTS) are more complex conditions than once thought. While previous research on BPH etiology tended to focus on testosterone and other hormones, more recent research suggests other factors may play a greater role in the development of BPH and LUTS - including inflammation, various growth factors, and adrenoreceptors.

BPH-associated LUTS include frequent urination and/or urgent need to urinate, waking at night to urinate (noc
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. AEterna Zentaris to Announce Third Quarter 2007 Financial and Operating Results on November 7, 2007
2. Amarin Announces Private Placement for up to $60 Million
3. NightHawk Radiology Holdings, Inc. Announces Dutch Tender Offer for Its Common Stock
4. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
5. Veria Announces Acquisition of Massage Envy Ltd.
6. TOFUTTI Announces First Quarter Results
7. Natural Alternatives International, Inc. Announces Third Quarter Results
8. eDiets.com(R) Announces Q1 2008 Results
9. Boston Scientific Announces FDA Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
10. United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results
11. The Blue Foundation for a Healthy Florida Announces $8 Million Initiative to Address Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... (PRWEB) August 22, 2014 The regional ... Toyota Indiana is on the grow again. ... jobs by summer 2016 to boost production of the ... bring Toyota Indiana’s overall investment to $4 billion. This ... America while providing additional flexibility to adjust its product ...
(Date:8/22/2014)... 2014 As the controversy surrounding ... in uterine surgeries continues to grow, Bernstein Liebhard ... decided to limit coverage of uterine morcellation. According ... Cross-Blue Shield of Massachusetts will no longer cover ... as of September 1, 2014. Other insurers in ...
(Date:8/22/2014)... protein 11 (BIM) deletion in advanced non-small cell ... free survival (PFS) in epidermal growth factor receptor ... Asian patients. Also, BIM deletion independently predicts overall ... BIM protein can activate the programmed cell death ... BIM deletion has been detected in 12.8% of ...
(Date:8/22/2014)... Restore My Vision Today , a ... to help people discover how they can get rid ... instead improving their eyesight naturally has caught the attention ... “There’s a reason why the glasses and contacts industry ... people just assume that it’s their only option to ...
(Date:8/22/2014)... Hudson County, NJ (PRWEB) August 22, 2014 ... that a leading specialist in Internal Medicine, Geriatrics, ... joined the network, CarePoint Health Medical Group. Their ... of highly skilled and experienced physicians comprise CarePoint ... doctors and practices in Hudson County, representing a ...
Breaking Medicine News(10 mins):Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Dr. Reisner Joins CarePoint Health Medical Group 2
... LLC, is proud to announce the latest benefits and features on ... ... -- Healthy Directions, LLC, is proud to announce the latest benefits ... premium quality, doctor-formulated products that address a wide range of health ...
... levels of psychological distress than those who are more ... European Society for Medical Oncology,s Symposium on Cancer and ... a common problem in cancer. It is estimated that ... weight loss and malnutrition during the course of their ...
... is needed is a new classification system and an overall standardization ... neurotrauma expert Geoff Manley, MD, PhD, professor of neurological surgery, co-director ... neurotrauma at UCSF-affiliated San Francisco General Hospital. , ... ...
... and cancer plays a major role in this disparity. African ... present at a later, deadlier stage; and they have poorer ... what extent are each of these three factors responsible for ... in Journal of General Internal Medicine Feb. 18, ...
... 17, 2009, the first of two effective dates in ... goes into effect. This final rule adopts Accredited ... and National Council for Prescription Drug Programs (NCPDP) Versions ... Compliance with these standards is mandatory by January 1, ...
... key to treatment, scientists say , , FRIDAY, March 20 ... an important role in the severe lung damage suffered ... Their findings may open up new targets for treatment ... United States. , "Cystic fibrosis patients have a problem ...
Cached Medicine News:Health News:Healthylivingnetwork.com Announces Web Site Enhancements and Additional Product Offerings 2Health News:Healthylivingnetwork.com Announces Web Site Enhancements and Additional Product Offerings 3Health News:Focus on treating malnutrition in cancer patients, researchers say 2Health News:Traumatic Brain Injury: UCSF Neurosurgeon Calls For More Research, Improved Treatment Standard 2Health News:Traumatic Brain Injury: UCSF Neurosurgeon Calls For More Research, Improved Treatment Standard 3Health News:Study quantifies racial disparities in cancer mortality rates between blacks and whites 2Health News:Edifecs Announces New Version of Its Integrated HIPAA 5010 and ICD-10 Analysis and Migration Solution 2Health News:Edifecs Announces New Version of Its Integrated HIPAA 5010 and ICD-10 Analysis and Migration Solution 3Health News:Insights Give New Hope Against Cystic Fibrosis 2
(Date:8/22/2014)... 22, 2014  Mark Riccio, director of Cornell ... is using the online crowd-funding platform Kickstarter to ... to researchers and would-be superheros everywhere: "for FREE." ... YOU do if you had Superman,s X-ray vision?" ... explorers everywhere, from elementary through high school students, ...
(Date:8/22/2014)... 22, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today ... units of common stock and warrants at a price ... million, prior to deducting underwriting discounts and commissions and ... warrants are immediately separable and will be issued separately.  ... trading on The NASDAQ Stock Market under the ticker ...
(Date:8/21/2014)... , Aug. 21, 2014  eRelevance Corporation ( ... announced today that it has completed integration with ... for Plastic Surgery and Dermatology practices. ... value to healthcare practices using Nextech," stated ... Corporation. "Using information from the EMR we are ...
Breaking Medicine Technology:Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4eRelevance Corporation Integrates with Nextech Electronic Medical Records 2
Thompson surgical radiotranslucent anterior lumbar retractor system....
... is the first true high-speed, high-torque touch control ... comparable to Legend Gold and runs at 73,000 ... design provides ergonomic positioning and true variable speed ... the Legend Gold Touch is also smaller, with ...
... The METRx Microdiscectomy System incorporates specially designed ... a surgical area in a minimally invasive ... diameter size from 5.3 mm to 20.8 ... inserted sequentially - one around the other ...
... System, a uniquely designed system combining ... two systems into one. Detachable blade ... site during retractor placement, providing better ... retractor body slides easily onto the ...
Medicine Products: